SEATTLE, Jan. 19, 2022 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the China ulcerative colitis market is estimated to be valued at US$ 185 million in 2021 and is expected to exhibit a CAGR of 2.9% over the forecast period (2021-2028).
Key Trends and Analysis of the China Ulcerative Colitis Market:
Key trends in the market include growing prevalence of ulcerative colitis, increase in lifestyle related risk factors, emergence of biosimilars, ongoing clinical trials, rise in drug approvals and launches, increasing R&D expenditure, and increasing collaborations, partnerships, mergers, and acquisitions among key players. These key trends are expected to aid in growth of the China Ulcerative Colitis Market.
For instance, in February 2021, the supplemental New Drug Application (sNDA) of Bristol Myers Squibb for Zeposia (ozanimod) was accepted by the U.S. Food and Drug Administration (FDA) to treat adult patients suffering from moderate to severe ulcerative colitis (UC).
Moreover, increase in number of novel drug products in pipeline is expected to drive the market growth over the forecast period. For instance, in March 2021, Eli Lilly and Company, an American pharmaceutical company, announced that the Lucent-1 is the first monoclonal antibody is in phase III study for moderate to severe ulcerative colitis.
Request for Sample copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/4862
Furthermore, key players operating in the China ulcerative colitis market are focusing on adoption of inorganic growth strategies such as acquisitions, mergers, partnerships, and collaborations, in order to strengthen their market presence in the Chinese market.
For instance, in August 2021, Athos Therapeutics, Inc., a biotechnology company involved in the development of first-in-class precision therapeutics for patients with immune-mediated diseases, collaborated with Cleveland Clinic in Cleveland, Ohio. An aim of this agreement is to advance the precision medicine used in inflammatory bowel disease (IBD) conditions such as ulcerative colitis and Crohn's disease.
Key Market Takeaways:
The China ulcerative colitis market is expected to exhibit a CAGR of 2.9 % over the forecast period, owing to rising product approvals. For instance, in March 2020, Takeda Pharmaceutical Co. Ltd, a Japanese multinational pharmaceutical company received approval for Entyvio (Vedolizumab) by China’s National Medical Products Administration (NMPA). It is a gut selective biologic authorized to treat moderate to severe ulcerative colitis and Crohn's disease for adults in China who were intolerant or less responsive to conventional therapies or tumor necrosis factor alpha (TNFα) inhibitors.
Among drug therapy, 5-Aminosalicylates segment accounted for largest market share in 2021 owing to rising drug product launches, which leads to increased demand for ulcerative colitis drug therapy. For instance, in July 2021, Tillotts Pharma AG part of the Japanese Zeria Group, launched Asacol (mesalazine) as first-line therapy for mild to moderate ulcerative in China.
Key players operating in the China ulcerative colitis market include AbbVie Inc., Celltrion Healthcare, Johnson & Johnson Services, Inc., F. Hoffmann-La Roche AG, Arena Pharmaceuticals, Takeda Pharmaceuticals Company Ltd., GlaxoSmithKline Plc., Eli Lilly and Company, AstraZeneca, Pfizer Inc., Amgen, BRISTOL-MYERS SQUIBB, Finch Therapeutics Group, Inc., Athos Therapeutics, Inc., Teva Pharmaceutical Industries Ltd., and Tillotts Pharma AG.
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/4862
China Ulcerative Colitis Market, By Drug Therapy:
China Ulcerative Colitis Market, By Route of Administration:
China Ulcerative Colitis Market, By Distribution Channel:
Related Market Intelligence Reports:
Tumor Necrosis Factor (TNF) Inhibitor Drugs Market, By Drug Type (Etanercept, Infliximab, Adalimumab, Certolizumab, and Golimumab), By Indication (Rheumatoid Arthritis, Juvenile Arthritis, Psoriatic Arthritis, Plaque Psoriasis, Ankylosing Spondylitis, Ulcerative Colitis, Crohn's Disease, and Others), By Route of Administration (Subcutaneous Injection and Intravenous injection), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027
Inflammatory Bowel Disease Market, by Drug Class (Corticosteroids, Aminosalicylates, TNF Inhibitors, Immunosuppressant, Antibiotics, and Others), by Disease Indication (Ulcerative Colitis and Crohn’s Disease), by Route of Administration (Oral and Injectable), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
CONTACT: Mr. Shah Senior Client Partner – Business Development Coherent Market Insights Phone: US: +1-206-701-6702 UK: +44-020-8133-4027 Japan: +81-050-5539-1737 India: +91-848-285-0837 Email: email@example.com Website: https://www.coherentmarketinsights.com